Saved in this browser. Sign in to sync across devices.
What we know: Vanda reported on October 14, 2026 that Study 3201 did not meet its primary or key secondary endpoint. This is a sponsor report; a full independent journal publication may add detail. The investigational medicine VQW-765 is not an FDA-approved social anxiety treatment, and its development program is on hold while the company reviews the data.
What was the study designed to test?
Study 3201 (NCT07221578) randomized 546 adults aged 18–65 with social anxiety disorder at approximately 30 U.S. sites. Participants received a single dose of VQW-765 or placebo before a structured social stress challenge that included preparing and giving an interview-style presentation to an unresponsive panel.
VQW-765 is an experimental alpha-7 nicotinic acetylcholine receptor partial agonist. Researchers tested whether it could reduce acute, on-demand distress during that challenge, not whether it would treat every feature of social anxiety over time.
PRIMARY OUTCOME · WOMEN
65.6 vs 66.0
Mean distress scores were 65.6 with VQW-765 and 66.0 with placebo on a 0–100 scale (p=0.8899). No statistically significant difference was found.
KEY SECONDARY · ALL PARTICIPANTS
64.7 vs 63.8
In women and men combined, the VQW-765 group scored 64.7 versus 63.8 with placebo (p=0.6605). This endpoint also did not meet the study goal.
EARLIER EVIDENCE
Phase 2 did not predict Phase 3
A smaller earlier study suggested numerically lower distress. The larger confirmatory trial did not reproduce a meaningful advantage over placebo.
DEVELOPMENT STATUS
Program paused
Vanda placed the VQW-765 development program on hold pending a more complete analysis of the trial data. This is not an FDA treatment approval.
Does a negative trial prove the medicine never works?
No. A failed primary endpoint means that this trial did not demonstrate the prespecified benefit under the conditions tested. Researchers can explore differences in dose, populations, endpoints and measurement, but such analyses do not override a failed confirmatory result. New controlled evidence would be required to establish benefit.
Vanda described the medication as generally well tolerated in this study. That is a sponsor-reported short-term safety observation and should not be mistaken for evidence of effectiveness or a fully characterized long-term safety profile.
What should someone with social anxiety do with this information?
It does not change established approaches to social anxiety. Evidence-based psychotherapy, including cognitive behavioral therapy, and appropriate prescribed medications remain options to discuss with a qualified clinician. There is no reason to postpone care for VQW-765.
Why NeuroCoach covers trials that do not succeed
- It prevents false hope: A new mechanism or promising small trial is not proof that a medication will help.
- It improves research literacy: The main endpoint is chosen before the trial, not after the results are known.
- It respects participants: Negative results advance medical knowledge and can prevent ineffective treatments from moving forward without evidence.
- It helps families evaluate headlines: Large studies can overturn earlier assumptions.
Useful questions to ask about any trial
Was it randomized? What was the prespecified primary outcome? What were the results relative to placebo? Were the findings peer reviewed? Who was studied, for how long, and what adverse events were reported?
Explore registered clinical trials →Primary sources and clinical context
- Vanda Pharmaceuticals — October 14, 2026 Phase 3 results announcement ↗
Sponsor-reported trial results; full peer-reviewed publication not yet available
- ClinicalTrials.gov — Study NCT07221578 ↗
Official registration for VP-VQW-765-3201; registry updates can lag announcements
- NIMH — Social anxiety disorder: more than just shyness ↗
Established social anxiety assessment and treatment information
Sources checked October 16, 2026 · Clinical editorial review pending. Educational information, not a prescription or individualized medical advice.